Multi-drug-resistant tuberculosis cost-effectiveness of therapy

Revision as of 20:25, 26 September 2014 by Alejandro Lemor (talk | contribs)
Jump to navigation Jump to search

Multi-drug-resistant tuberculosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multi-drug-resistant tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multi-drug-resistant tuberculosis cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multi-drug-resistant tuberculosis cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multi-drug-resistant tuberculosis cost-effectiveness of therapy

CDC on Multi-drug-resistant tuberculosis cost-effectiveness of therapy

Multi-drug-resistant tuberculosis cost-effectiveness of therapy in the news

Blogs on Multi-drug-resistant tuberculosis cost-effectiveness of therapy

Directions to Hospitals Treating Multi-drug-resistant tuberculosis

Risk calculators and risk factors for Multi-drug-resistant tuberculosis cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]

Overview

Cost-effectiveness of therapy

  • The average cost of treating a person with TB disease increases with greater resistance.
  • Direct costs (in 2010 U.S. dollars) average from $17,000 to treat drug-susceptible TB to $430,000 to treat the most drug-resistant form of the disease (XDR TB). [1]
  • When including productivity losses (e.g., lost income) experienced by patients while undergoing treatment, costs are even higher.[1]
Image obtained from CDC[1]

References

  1. 1.0 1.1 1.2 "CDC Drug-Resistant TB".

Template:WH Template:WS